溃疡性结肠炎患者升级至生物制剂治疗时联用5-氨基水杨酸无获益:临床试验个体参与者数据的汇总分析
该研究汇总了5项英夫利西单抗和戈利木单抗治疗中重度溃疡性结肠炎(UC)的临床试验个体参与者数据,共纳入2183例患者(1715例[78.6%]联用5-氨基水杨酸[5-ASA])。多因素logistic回归分析显示,联用5-ASA与临床缓解(调整OR 0.67,95%CI 0.45-1.01,p=0.06)、临床应答(aOR 0.89,95%CI 0.60-1.33,p=0.58)及黏膜愈合(aOR 1.12,95%CI 0.82-1.51,p=0.48)均无显著关联。结论认为,在中重度UC患者升级至抗TNF治疗时,继续使用5-ASA不改善临床结局。
要点
- 中重度UC患者升级至英夫利西单抗或戈利木单抗治疗时,联用5-ASA与临床缓解、临床应答及黏膜愈合均无显著关联。
- 联用5-ASA组与未联用组相比,临床缓解的调整OR为0.67(95%CI 0.45-1.01,p=0.06),未达统计学显著。
- 该关联在诱导治疗与维持治疗试验中、以及英夫利西单抗与戈利木单抗试验中均一致。
核心结论
- 基于个体参与者数据汇总分析,在中重度UC患者升级至抗TNF治疗时,继续使用5-ASA不改善临床结局。
研究设计与样本
- 研究为个体参与者数据(IPD)汇总分析,纳入5项英夫利西单抗和戈利木单抗治疗中重度UC的临床试验(ACT-1、ACT-2、PURSUIT-SC、PURSUIT-M、NCT00336492)。
- 共纳入2183例接受英夫利西单抗或戈利木单抗治疗的患者,其中1715例(78.6%)联用5-ASA。
- 主要结局为各试验末次随访时的临床缓解(Mayo临床评分<3);次要结局为临床应答和黏膜愈合。
- 采用多因素logistic回归分析,调整性别、吸烟、基线疾病活动度、病变范围、生化指标(C反应蛋白、白蛋白、血红蛋白)及联用泼尼松和免疫调节剂。
主要发现
- 联用5-ASA与临床缓解的odds无显著关联(调整OR 0.67,95%CI 0.45-1.01,p=0.06)。
- 联用5-ASA与临床应答无显著关联(aOR 0.89,95%CI 0.60-1.33,p=0.58)。
- 联用5-ASA与黏膜愈合无显著关联(aOR 1.12,95%CI 0.82-1.51,p=0.48)。
- 上述结果在诱导治疗与维持治疗试验中、以及英夫利西单抗与戈利木单抗试验中均一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: 5-aminosalicylates (5-ASA) are frequently continued in patients with moderate-severe ulcerative colitis (UC), even after escalation to biologic agents, without evaluation of the benefit of this approach. We conducted an individual participant data (IPD) pooled analysis of trials of infliximab and golimumab in UC, to evaluate whether concomitant use of 5-ASA modifies clinical outcomes among anti-tumor necrosis factor (TNF)-α-treated patients. METHODS: We included IPD from five trials of infliximab and golimumab in patients with moderate-severe UC (ACT-1 and -2, PURSUIT-SC, PURSUIT-M, NCT00336492). Patients treated with infliximab or golimumab were categorized as receiving concomitant 5-ASA or not at time of trial entry. Primary outcome was clinical remission (Mayo Clinic Score < 3) at last follow-up for each trial; secondary outcomes were clinical response and mucosal healing. Using multivariable logistic regression analysis, we evaluated association between concomitant 5-ASA and clinical remission, after adjusting for sex, smoking, baseline disease activity, disease extent, biochemical variables (C-reactive protein, albumin, hemoglobin), and concomitant prednisone and immunomodulators. RESULTS: We included 2183 infliximab-treated or golimumab-treated patients (1715 [78.6%] on 5-ASA). Concomitant use of 5-ASA was not associated with odds of achieving clinical remission (adjusted OR, 0.67 [95% CI, 0.45-1.01], p = 0.06), clinical response (aOR, 0.89 [0.60-1.33], p = 0.58) or mucosal healing (aOR, 1.12 [0.82-1.51], p = 0.48). These results were consistent in trials of induction and maintenance therapy, and in trials of infliximab and golimumab. CONCLUSIONS: Based on IPD pooled analysis, in patients with moderate-severe UC who are escalated to anti-TNF therapy, continuing 5-ASA does not improve clinical outcomes.
引用
- Singh S, Proudfoot JA, Dulai PS, et al. No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. Am J Gastroenterol. 2018. PMID: 29925913. doi:10.1038/s41395-018-0144-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。